Navigation Links
Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
Date:12/8/2008

AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

"This is an important strategic milestone in the development of Reviroc(TM) and we are very pleased with the orphan drug designations received from the FDA," says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval.

About Reviroc(TM)

Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development compan
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "North American ... Graft), by Application (Surgical Wound, & Ulcer), by ... to 2019" report to their offering. ,     ... care market is estimated to grow at a ...
(Date:5/21/2015)... 2015  Cardica, Inc. (Nasdaq: CRDC ) today announced ... , the company,s vice president of operations, was granted an ... at a per share exercise price of $0.43, the closing ... granted pursuant to Cardica, Inc.,s Inducement Plan, which was approved ... Rule 5653(c)(4) of the Nasdaq Global Market for equity grants ...
(Date:5/21/2015)... , May 21, 2015 ... Arzneimittelfälschungen - Zwecks Leistungsvergleich zur Expertise ... auf EG-Mitgliedstaaten verwiesen, in denen uneingeschränkt ... Wählen Sie ein Aegate-Land: beispielsweise BELGIEN ... zur Bekämpfung von Arzneimittelfälschungen (FMD) handelt ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Corporation (Nasdaq: DNDN ) today announced that ... Phase 1 clinical trial of D3263 in patients with ... drug candidate designed to target TRPM8 (a transmembrane cation ... The trial is an open-label, dose-escalation study evaluating ...
... strategies for personalized approach to cancer treatmentSEATTLE, April ... subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and ... which utilized RNA interference (RNAi) and bioinformatics to ... that enhance the anti-tumor response to the experimental ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
(Date:5/24/2015)... 2015 The Rolling Stones Zip ... San Diego at Petco Park. This iconic group is ... May 20th, they had a warmup show in Los Angeles ... in Los Angeles, this beloved band not only played their ... favorites such as "Jumping Jack Flash," "Moonlight Mile" and ...
(Date:5/24/2015)... 2015 Scientists with Cardno ChemRisk, a ... quality compliance issues that may have raised the risk ... has just posted an article on the research. ... group found airborne asbestos levels well above OSHA safety ... and 2011. , “Asbestos compliance sampling data associated with ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers are ... City exactly five years to the day after the disastrous ... large fire tore through the Branches United Methodist Church and ... middle of the night as neighbors, staff and Branches' children ... though it is suspected that the fire began accidentally. Branches ...
Breaking Medicine News(10 mins):Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... experience for consumers, ... employers and health care providers., CHARLOTTE, N.C. and LOS ... today announced a strategic relationship designed to,help employers, employees and ... care. (LOGO: http://www.newscom.com/cgi-bin/prnh/20050720/CLW086LOGO-b ) The partnership ...
... at the opening of Eurospine conference in ... ... OFIX ) (the Company) today announced it has,acquired the rights to ... InSWing is designed to alleviate the leg and back pain suffered by,individuals ...
... ANGELES, Oct. 2 California School Garden,Network (CSGN) ... Angeles Unified,School District, in partnership with Western Growers, ... University of,California Cooperative Extension,s Common Ground Program are ... -- a school garden resource,fair in Los Angeles. ...
... WASHINGTON Say nanotechnology, and geeks imagine iPhones, laptops ... of the 580 products in a newly updated ... items as tennis racquets, clothing, and health products. ... Nanotechnologies at www.nanotechproject.org/consumerproducts, the updated inventory includes Head ...
... September 29, over 850,people in 60 cities across the ... devised, the Crossfit Fight Gone Bad Challenge to,raise money ... Prostate Cancer,Foundation. Over 4,000 donors supported the cause by ... matching funds grant from Safeway, the,event raised over $546,000 ...
... Few Companies to Offer Both Suspension and Tablet Forms, ... a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced ... U.S. Food and,Drug Administration (U.S. FDA) to manufacture and ... 250 mg/5 mL. Ranbaxy is the first,company to have ...
Cached Medicine News:Health News:Health Net and Bank of America Launch Partnership 2Health News:Health Net and Bank of America Launch Partnership 3Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 2Health News:Orthofix International Acquires InSWing(TM) Interspinous Process Spacer 3Health News:'Growing Healthy with School Gardens' Takes Root in Los Angeles Saturday 2Health News:Nanotechnology: not just for geeks 2Health News:Crossfit Workout Challenge Raises Over $500,000 in Four Hours for Athletes for a Cure 2Health News:Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: